^
No biomarker
Rhabdomyosarcoma
dactinomycin
Sensitive: A1 - Approval
No biomarker
Rhabdomyosarcoma
IE
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
VAC
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
trabectedin
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
ADX-2191
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
vinorelbine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
topotecan
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
irinotecan
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
SA033
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
cyclophosphamide + vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
vincristine + dactinomycin
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
irinotecan + vincristine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
PD-L1 expression
Rhabdomyosarcoma
nivolumab
Sensitive: C1 - Off-label
BRAF-MAD1L1 fusion
Rhabdomyosarcoma
anlotinib
Resistant: C4 – Case Studies
PD-L1 expression
Rhabdomyosarcoma
pazopanib
Resistant: C4 – Case Studies
HRAS mutation
Rhabdomyosarcoma
tipifarnib
Sensitive: D – Preclinical
KDM1A overexpression
Rhabdomyosarcoma
SP2577
Sensitive: D – Preclinical
PAX3-FOXO1 fusion
Rhabdomyosarcoma
SNDX-275
Sensitive: D – Preclinical
HER-2 expression
Rhabdomyosarcoma
T-lymphocyte cell therapy
Sensitive: D – Preclinical